Achieve Life Sciences Reports Favorable Long-Term Safety Data for Cytisinicline — Achieve Life Sciences, Inc.

Event summary

Achieve Life Sciences presented 52-week safety data from the ORCA-OL study at the ATS 2026 Annual Meeting.
No new safety signals identified, with nausea reported in only 2.5% of participants over 52 weeks.
The ORCA-OL trial enrolled 475 adults using cigarettes, e-cigarettes, or both, with a median exposure of 361 days.
The data completes the clinical evidence package supporting Achieve's NDA for cytisinicline as a smoking cessation treatment.
Cytisinicline's NDA has a PDUFA date of June 20, 2026.

The big picture

Achieve Life Sciences' long-term safety data for cytisinicline comes at a critical juncture as the company awaits regulatory decision on its NDA. The data reinforces cytisinicline's potential to address a significant unmet need in smoking and e-cigarette cessation, particularly as tobacco use remains the leading cause of preventable death worldwide. The strategic focus now shifts to navigating the regulatory process and preparing for commercialization, with the FDA's PDUFA date looming in June 2026.

What we're watching

Regulatory Pathway: Whether the favorable long-term safety data will strengthen Achieve's NDA submission and expedite regulatory approval.
Market Potential: The pace at which cytisinicline can capture market share in the smoking cessation therapy space, given the lack of FDA-approved treatments for e-cigarette cessation.
Commercialization Strategy: How Achieve plans to position cytisinicline against existing treatments like varenicline, leveraging the comparative effectiveness data presented at ATS.